tiprankstipranks
Regions Financial’s Q2 Results Surpass Estimates; Street Says Buy
Market News

Regions Financial’s Q2 Results Surpass Estimates; Street Says Buy

Alabama-based bank Regions Financial Corp. (RF) has reported better-than-expected financial results for the second quarter of 2021. The company offers wealth management, commercial banking, retail banking, and mortgage products and services.

Earnings per share (EPS) totaled $0.77, compared to a loss of $0.25 in the second quarter of 2020. The EPS surpassed the Street’s estimate of $0.52. Total revenue increased 2.4% year-over-year to $1.58 billion, marginally surpassing analysts’ expectations of $1.55 billion.

Net interest income fell nearly 1% to $963 million; non-interest income grew 8% to $619 million; total deposits rose 18.2% to $131 million; and total loans declined 8.1% to $84.6 million. (See Regions stock chart on TipRanks)

The President and CEO of Regions Financial, John Turner, said, “We have taken several steps — adding talented bankers, investing in service and delivery channels, and enhancing our capabilities through our bolt-on acquisition strategy — to build on our momentum and create greater value for customers, communities, and shareholders over time.”

On July 6, KBW analyst David Konrad initiated coverage on the stock with a Sell rating and a price target of $18 (5.8% downside potential). The analyst said the Sell rating is based on “Regions’ challenges generating organic growth, its near-term reliance on derivative benefits and its outsized exposure to industry service charge/overdraft pressures.”

Overall, the stock has a Moderate Buy consensus based on 4 Buys, 4 Holds and 1 Sell. The average Regions Financial price target of $22.83 implies 19.5% upside potential. The company’s shares have gained 80% over the past year.

According to TipRanks’ Smart Score rating system, Regions Financial scores an 8 out of 10, suggesting that the stock is likely to outperform market averages.

Related News:
Kimberly Clark’s Q2 Results Miss Estimates, Guidance Lowered
Honeywell Raises Outlook on Outstanding Q2 Results
Cortexyme Develops 3CLpro Inhibitor to Treat COVID-19 Infection

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles